Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000691111 | SCV000818854 | uncertain significance | Familial acute necrotizing encephalopathy | 2021-09-02 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine with valine at codon 406 of the RANBP2 protein (p.Ile406Val). The isoleucine residue is highly conserved and there is a small physicochemical difference between isoleucine and valine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with RANBP2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C25"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004025071 | SCV003657594 | uncertain significance | not specified | 2022-11-08 | criteria provided, single submitter | clinical testing | The c.1216A>G (p.I406V) alteration is located in exon 9 (coding exon 9) of the RANBP2 gene. This alteration results from a A to G substitution at nucleotide position 1216, causing the isoleucine (I) at amino acid position 406 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |